

McLeod Health

Eculizumab (Soliris) Treatment Plan

Patient Name: _____ DOB: _____

Height (cm): _____ Weight (kg): _____ Allergies: _____

Patient Primary Phone Number: _____

Diagnosis (select one):

D59.5 Paroxysmal Nocturnal Hemoglobinuria D59.3 Atypical Hemolytic Uremic Syndrome

Other: ICD 10 Code: _____ Diagnosis Description: _____

Pre-Medications: **administered 30 minutes prior to infusion**

None (product information does not suggest any pre-medication prior to infusion)

- Acetaminophen 650 mg PO
- Diphenhydramine: Dose: 25 mg 50 mg Route: PO or IVP
- Methylprednisolone: Dose: 40 mg or 125 mg Route: IVP
- Famotidine: Dose: 20 mg Route: PO or IVPB

Drug Orders (select appropriate dosing and frequency):

- Eculizumab (Soliris) (J1300) IV diluted in Sodium Chloride 0.9% to a 5 mg/mL concentration infused over a minimum of 35 minutes. Each infusion will be followed with a 1 hour monitoring period.

- Dosing/Frequency for PNH:
 - Induction: 600 mg once weekly Weeks 1-4, followed by 900 mg once weekly Week 5
 - Maintenance: 900 mg once every 2 weeks
- Dosing/Frequency for aHUS:
 - Induction: 900 mg once weekly Weeks 1-4, followed by 1200 mg once weekly Week 5
 - Maintenance: 1200 mg once every 2 weeks

- Order Duration: One year unless otherwise specified (Other: _____)

Lab Orders:

Standing Orders:

- Infusion Reaction Protocol (CPOE-1396) will be activated if any hypersensitivity reaction occurs, including anaphylaxis. Infusion will be stopped and physician notified.
- Appropriate access and line care orders per health system policy

Physician Signature: _____ **Date:** _____

Physician Name: _____ **Phone:** _____

Pre-Screening Requirements:

- Documented meningococcal vaccination administration (at least 2 weeks prior to start of therapy)
- Documented prescriber enrollment in the Soliris REMS program and appropriate patient education required by REMS program

Previous Therapies:

- For new patient referrals, please send history and physical and most recent physician note with completed plan
- If patient has previously received eculizumab at another facility, please provide last date received: _____
- If patient has previously received another biologic therapy, please provide the name: _____
and the last date received: _____

Insurance Information:

Insurance Plan Name: _____

Insurance Identification Number: _____

Insurance Customer Service Contact Number: _____

Preferred Treatment Location

| | | |
|--|---|--|
| <input type="checkbox"/> McLeod Regional Medical Center (Florence) | <input type="checkbox"/> McLeod Health Loris | <input type="checkbox"/> McLeod Health Cheraw |
| <input type="checkbox"/> McLeod Health Seacoast (Little River) | <input type="checkbox"/> McLeod Health Dillon | <input type="checkbox"/> McLeod Health Clarendon (Manning) |

Fax completed Treatment Plan to the McLeod Medication Access Team at 843-777-9798. For any questions, please contact our team at medicationaccessteam@mcleodhealth.org.